Substrate-bound insulin-like growth factor (IGF)-I-IGF binding protein-vitronectin-stimulated breast cell migration is enhanced by coactivation of the phosphatidylinositide 3-Kinase/AKT pathway by alphav-integrins and the IGF-I receptor.

IGF-I can bind to the extracellular matrix protein vitronectin (VN) through the involvement of IGF-binding proteins-2, -3, -4, and -5. Because IGF-I and VN have established roles in tumor cell dissemination, we were keen to investigate the functional consequences of the interaction of IGF-I, IGF binding proteins (IGFBPs), and VN in tumor cell biology. Hence, functional responses of MCF-7 breast carcinoma cells and normal nontumorgenic MCF-10A mammary epithelial cells were investigated to allow side-by-side comparisons of these complexes in both cancerous and normal breast cells. We demonstrate that substrate-bound IGF-I-IGFBP-VN complexes stimulate synergistic increases in cellular migration in both cell types. Studies using IGF-I analogs determined this stimulation to be dependent on both heterotrimeric IGF-I-IGFBP-VN complex formation and the involvement of the IGF-I receptor (IGF-IR). Furthermore, the enhanced cellular migration was abolished on incubation of MCF-7 and MCF-10A cells with function blocking antibodies directed at VN-binding integrins and the IGF-IR. Analysis of the signal transduction pathways underlying the enhanced cell migration revealed that the complexes stimulate a transient activation of the ERK/MAPK signaling pathway while simultaneously producing a sustained activation of the phosphatidylinositide 3-kinase/AKT pathway. Experiments using pharmacological inhibitors of these pathways determined a requirement for phosphatidylinositide 3-kinase/AKT activation in the observed response. Overexpression of wild type and activated AKT further increases substrate-bound IGF-I-IGFBP-VN-stimulated migration. This study provides the first mechanistic insights into the action of IGF-I-IGFBP-VN complexes and adds further evidence to support the involvement of VN-binding integrins and their cooperativity with the IGF-IR in the promotion of tumor cell migration.

[1]  A. Jemal,et al.  Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.

[2]  D. Cheresh,et al.  Vitronectin and its receptors. , 1993, Current opinion in cell biology.

[3]  D. Cheresh,et al.  Glioblastoma expression of vitronectin and the alpha v beta 3 integrin. Adhesion mechanism for transformed glial cells. , 1991, The Journal of clinical investigation.

[4]  N. Masuyama,et al.  Akt mediates Rac/Cdc42-regulated cell motility in growth factor-stimulated cells and in invasive PTEN knockout cells , 2001, Current Biology.

[5]  Meenhard Herlyn,et al.  Axis of evil: molecular mechanisms of cancer metastasis , 2003, Oncogene.

[6]  N. Masuyama,et al.  The PI3K‐Akt pathway promotes microtubule stabilization in migrating fibroblasts , 2007, Genes to cells : devoted to molecular & cellular mechanisms.

[7]  T. Nam,et al.  Thrombospondin and osteopontin bind to insulin-like growth factor (IGF)-binding protein-5 leading to an alteration in IGF-I-stimulated cell growth. , 2000, Endocrinology.

[8]  Sandra,et al.  A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer. , 1998, Cancer research.

[9]  L. Maile,et al.  Insulin-like Growth Factor I Increases (cid:1) V (cid:2) 3 Affinity by Increasing the Amount of Integrin-associated Protein That Is Associated with Non-raft Domains of the Cellular Membrane* , 2002 .

[10]  J. Wallace,et al.  Mutations in the B-domain of insulin-like growth factor-I influence the oxidative folding to yield products with modified biological properties. , 1995, The Biochemical journal.

[11]  S. Haslam,et al.  Proliferation of mouse mammary epithelial cells in vitro: interactions among epidermal growth factor, insulin-like growth factor I, ovarian hormones, and extracellular matrix proteins. , 2000, Endocrinology.

[12]  J. Wallace,et al.  Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency. , 1992, Journal of molecular endocrinology.

[13]  Zee Upton,et al.  Insulin-like growth factors (IGF) and IGF-binding proteins bound to vitronectin enhance keratinocyte protein synthesis and migration. , 2004, The Journal of investigative dermatology.

[14]  K. Yamada,et al.  Integrins can collaborate with growth factors for phosphorylation of receptor tyrosine kinases and MAP kinase activation: roles of integrin aggregation and occupancy of receptors , 1996, The Journal of cell biology.

[15]  M. Schwartz,et al.  Integrin beta 1- and beta 3-mediated endothelial cell migration is triggered through distinct signaling mechanisms , 1993, The Journal of cell biology.

[16]  Y. Murakumo,et al.  Akt/PKB regulates actin organization and cell motility via Girdin/APE. , 2005, Developmental cell.

[17]  S. Dunn,et al.  The insulin‐like growth factor‐1 elevates urokinase‐type plasminogen activator‐1 in human breast cancer cells: A new avenue for breast cancer therapy , 2000, Molecular carcinogenesis.

[18]  J. Brugge,et al.  Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial–mesenchymal transition , 2005, The Journal of cell biology.

[19]  B. Eliceiri.  This Review is part of a thematic series on Integrins, which includes the following articles: Integrins and the Myocardium Functional Consequences of Integrin Gene Mutations in Mice Integrins in Vascular Development Integrin and Growth Factor Receptor Crosstalk , 2001 .

[20]  D E Ingber,et al.  Convergence of integrin and growth factor receptor signaling pathways within the focal adhesion complex. , 1995, Molecular biology of the cell.

[21]  R. O'Connor,et al.  Insulin-Like Growth Factor I Controls a Mutually Exclusive Association of RACK1 with Protein Phosphatase 2A and β1 Integrin To Promote Cell Migration , 2006, Molecular and Cellular Biology.

[22]  D. Leavesley,et al.  Insulin-like growth factor-II bound to vitronectin enhances MCF-7 breast cancer cell migration. , 2003, Endocrinology.

[23]  D. Yee,et al.  Inhibitors of Insulin-like Growth Factor Signaling: A Therapeutic Approach for Breast Cancer , 2006, Journal of Mammary Gland Biology and Neoplasia.

[24]  D. Clemmons,et al.  Blocking ligand occupancy of the αVβ3 integrin inhibits insulin-like growth factor I signaling in vascular smooth muscle cells , 1998 .

[25]  E. Tokunaga,et al.  Activation of PI3K/Akt signaling and hormone resistance in breast cancer , 2006, Breast cancer.

[26]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.

[27]  Adrian V. Lee,et al.  A Dominant Negative Type I Insulin-like Growth Factor Receptor Inhibits Metastasis of Human Cancer Cells* , 2004, Journal of Biological Chemistry.

[28]  P. Black,et al.  αvβ3 and αvβ5 Integrin Expression in Glioma Periphery , 2001 .

[29]  Zee Upton,et al.  Structural and functional evidence for the interaction of insulin-like growth factors (IGFs) and IGF binding proteins with vitronectin. , 2003, Endocrinology.

[30]  G. Botti,et al.  Vitronectin binding to urokinase receptor in human breast cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  D. Hadsell.  The insulin-like growth factor system in normal mammary gland function. , 2003, Breast disease.

[32]  Joseph J. Pereira,et al.  Bimolecular Interaction of Insulin-Like Growth Factor (IGF) Binding Protein-2 with αvβ3 Negatively Modulates IGF-I-Mediated Migration and Tumor Growth 1 , 2004, Cancer Research.

[33]  H. Rus,et al.  Persistent complement activation on tumor cells in breast cancer. , 1992, The American journal of pathology.

[34]  D. Leavesley,et al.  Responses of keratinocytes to substrate-bound vitronectin: growth factor complexes. , 2005, Experimental cell research.

[35]  L. Languino,et al.  beta1A integrin expression is required for type 1 insulin-like growth factor receptor mitogenic and transforming activities and localization to focal contacts. , 2005, Cancer research.

[36]  D. Clemmons,et al.  Extracellular matrix contains insulin-like growth factor binding protein-5: potentiation of the effects of IGF-I , 1993, The Journal of cell biology.

[37]  J. Wallace,et al.  Characteristics of binding of insulin-like growth factor (IGF)-I and IGF-II analogues to the type 1 IGF receptor determined by BIAcore analysis. , 2002, European journal of biochemistry.

[38]  J. Rhim,et al.  Selective modulation of type 1 insulin-like growth factor receptor signaling and functions by β1 integrins , 2004, The Journal of cell biology.

[39]  R. Baxter,et al.  Cellular actions of the insulin-like growth factor binding proteins. , 2002, Endocrine reviews.

[40]  J. Holly,et al.  IGFBPs and breast cancer. , 2003, Breast disease.

[41]  J. Uhm,et al.  Vitronectin, a glioma-derived extracellular matrix protein, protects tumor cells from apoptotic death. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[42]  D. Leroith,et al.  The role of the IGF system in cancer growth and metastasis: overview and recent insights. , 2007, Endocrine reviews.

[43]  M E Doerr,et al.  The Roles of Integrins and Extracellular Matrix Proteins in the Insulin-like Growth Factor I-stimulated Chemotaxis of Human Breast Cancer Cells (*) , 1996, The Journal of Biological Chemistry.

[44]  L. Maile,et al.  Interaction between Insulin-Like Growth Factor-I Receptor and αVβ3 Integrin Linked Signaling Pathways: Cellular Responses to Changes in Multiple Signaling Inputs , 2005 .

[45]  P. Vielh,et al.  Comparative distribution of fibronectin and vitronectin in human breast and colon carcinomas. An immunofluorescence study. , 1988, American journal of clinical pathology.

[46]  C. Smart,et al.  The Proliferative and Migratory Activities of Breast Cancer Cells Can Be Differentially Regulated by Heparan Sulfates* , 2000, The Journal of Biological Chemistry.

[47]  T. Meyer,et al.  Expression of alphav integrins and vitronectin receptor identity in breast cancer cells. , 1998, British Journal of Cancer.

[48]  N. Hay,et al.  The Akt-mTOR tango and its relevance to cancer. , 2005, Cancer cell.

[49]  L. Maile,et al.  The heparin binding domain of vitronectin is the region that is required to enhance insulin-like growth factor-I signaling. , 2006, Molecular endocrinology.

[50]  J. Woodgett,et al.  PKB/AKT: functional insights from genetic models , 2001, Nature Reviews Molecular Cell Biology.

[51]  R. Baserga.  The IGF-I receptor in cancer research. , 1999, Experimental cell research.

[52]  P. Bornstein,et al.  Control of smooth muscle cell growth by components of the extracellular matrix: autocrine role for thrombospondin. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[53]  L. Maile,et al.  Role of the integrin αVβ3 in mediating increased smooth muscle cell responsiveness to IGF-I in response to hyperglycemic stress , 2007 .

[54]  T. Wood,et al.  Gene-targeting and transgenic approaches to IGF and IGF binding protein function. , 1995, The American journal of physiology.

[55]  A. Toker,et al.  Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT. , 2005, Molecular cell.

[56]  P. Andreasen,et al.  Vitronectin in human breast carcinomas. , 2003, Biochimica et biophysica acta.

[57]  S. E. Knowles,et al.  Anabolic effects of insulin-like growth factor-I (IGF-I) and an IGF-I variant in normal female rats. , 1993, The Journal of endocrinology.

[58]  L. Maile,et al.  Insulin-like growth factor-i signaling in smooth muscle cells is regulated by ligand binding to the 177CYDMKTTC184 sequence of the β3-subunit of αVβ3 , 2006 .

[59]  H. Koh,et al.  Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase production. , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[60]  R. O'Connor,et al.  Regulation of IGF-I Receptor Signaling in Tumor Cells , 2003, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[61]  J. Testa,et al.  AKT activation up-regulates insulin-like growth factor I receptor expression and promotes invasiveness of human pancreatic cancer cells. , 2001, Cancer research.

[62]  S. Andò,et al.  Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells. , 2001, Cancer research.

[63]  R. Klemke,et al.  Insulin-like growth factor receptor cooperates with integrin alpha v beta 5 to promote tumor cell dissemination in vivo. , 1997, The Journal of clinical investigation.

[64]  J. Mcmurtry,et al.  Identification of vitronectin as a novel insulin-like growth factor-II binding protein. , 1999, Endocrinology.